Tempest is advancing TPST-1120, a first-in-class antagonist against peroxisome proliferator-activated receptor alpha (PPARα). PPARα is a transcription factor that regulates fatty acid oxidation (FAO) and inflammation.
PPARα is a Central Regulator of Fatty Acid Oxidation
Tempest and our research partners have demonstrated that blocking PPARα with TPST-1120 promotes a more inflamed tumor microenvironment (TME) through decreased FAO. Mediated by the inhibition of FAO, TPST-1120 shifts the metabolic balance of immune cells towards glycolysis and favors the bioenergetic needs of effector immune cell populations, including M1 tumor associated macrophages (TAMs) and effector T Cells (Teff). Treatment with TPST-1120 does not support the bioenergetic needs of immunosuppressive cell populations including M2 macrophages, myeloid suppressor cells and regulatory T cells, all of which utilize FAO.
Inhibition of FAO Promotes Inflamed Cell Phenotypes
TPST-1120 has shown efficacy in multiple syngeneic tumor models both as a single agent and in combination with anti-cancer therapies. The molecule is now being evaluated in a multi-site Phase 1/1b clinical study.
Trial Summary: TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Trial Identifier: NCT03829436